View:
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): December 20, 2006
SIGA
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-23047
|
13-3864870
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
file number)
|
(I.R.S.
employer
identification
no.)
|
|
420
Lexington Avenue, Suite 408
New
York, New York
(Address
of principal executive offices)
|
10170
(Zip
code)
|
Registrant’s
telephone number, including area code: (212) 672-9100
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
r
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r
Soliciting
material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other
Events.
On
December 20, 2006, PharmAthene, Inc. ("PharmAthene") filed a complaint (the
“Complaint”) against SIGA Technologies, Inc. (“SIGA”) in the Delaware Chancery
Court. PharmAthene's complaint alleges that it has the right to license
exclusively development and marketing rights for SIGA’s drug candidate,
SIGA-246, pursuant to, among other things, the recently terminated merger
agreement between the parties. PharmAthene's complaint further alleges that
SIGA
failed to negotiate the terms of such license in good faith and otherwise failed
to grant such license, and it seeks to compel SIGA to enter into such license
and pay unspecified damages. SIGA believes that the complaint lacks merit and
intends to contest vigorously the alleged claims.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
SIGA
TECHNOLOGIES,
INC.
By:
/s/
Thomas N.
Konatich
Name: Thomas
N.
Konatich
Title:
Chief
Financial Officer and
Acting
Chief
Executive Officer
Date: December
22, 2006